Hope, Progress, and the Future of Cholangiocarcinoma Research The 2026 Cholangiocarcinoma Foundation Conference brought together patients, caregivers, clinicians, researchers, advocates, and industry partners in Salt Lake City to share the latest progress in cholangiocarcinoma research and care.1 A key message from the conference was clear: research in cholangiocarcinoma is advancing rapidly, but access to appropriate testing, clinical trials, and expert care remains essential. Molecular...

Missed the webinar? Watch it on our C3 YouTube

Dear C3 Community, We’re pleased to share an update on the progress on the C3-led clinical trial, “STAR-BD01,” which will use Tumour Infiltrating Lymphocyte (TIL) therapy to treat people living with biliary tract cancers in Canada. This trial represents hope for many people across Canada, and we remain committed to keeping you informed with transparency to manage expectations as we move forward. From the very beginning, our goal with this trial has remained clear: to deliver the...